Swiss pharmaceutical company Novartis is investing $300 million ($288 million) in biotherapeutics development, which includes a new $100 million biologics hub at its home base in Basel.
This content was published on
1 minute
swissinfo.ch/mga
Português
pt
Novartis vai gastar 300 milhões de dólares em bioterapias
A further $110 million will be spent on research and production at a Novartis site in Slovenia and $60 million in Austria, the company announcedExternal link on Monday.
Biotherapeutics is a growing class of medicaments which are extracted or synthesized from biological material, including proteins, cells and genes to treat such conditions as cancer and autoimmune diseases.
“Across the industry, biotherapeutics account for almost one-half of all recent new drug approvals and have enormous potential to address unmet need across a wide range of diseases,” said Reto Fischer, Head of Technical Research Division, Global Drug Development.
The new Swiss biologics hub will be created on the Basel St Johann campus in Basel to complement the company’s existing NIBR biologics centre.
The Basel-headquartered Novartis, one of the world’s largest pharmaceutical companies, is currently undergoing a restructuring process. In June, it announced that 8,000 jobs would be cut from its 108,000 global work force. The 1,400 Swiss jobs that will disappear represents some 10% of the staff it employs in its home market.
Ai Weiwei expresses surprise at being turned away at Zurich Airport
This content was published on
The world-famous artist was stopped when he entered Switzerland on Monday evening because, according to the Zurich police, he did not have a visa.
This content was published on
Director General Tedros Adhanom Ghebreyesus says the American "absence" on the executive board since last week makes him "sad".
Number of bearded vultures in the Alps could double in ten years
This content was published on
The bearded vultures in the Alps are currently doing so well that their population could double to around 700 animals within ten years.
Hardly any violations of minimum wage regulations in Ticino
This content was published on
A good 3% of companies inspected have violated the minimum wage in the Swiss canton of Ticino in the past three years, according to an official review.
Mandatory EU referendum not possible, says Swiss commission
This content was published on
Switzerland's treaties with the European Union cannot be subject to a mandatory referendum. This is the opinion of the majority of the responsible committee of the House of Representatives.
Consumer group files legal complaint against Swiss shoemaker On
This content was published on
The consumer affairs bureau of French-speaking Switzerland has filed a legal complaint against On accusing it of greenwashing.
This content was published on
Thomas Schinecker, CEO of Swiss pharma firm Roche, has dismissed fears that sales targets would be under threat by US tariffs.
This content was published on
The recent decision by the Swiss drugmaker to shed 7% of its workforce is more than just a cost-cutting measure - it’s a turning point for Novartis.
Novartis job cuts to heavily impact management roles
This content was published on
Of the 1,400 job cuts announced by the pharma giant in Switzerland, up to half of them will involve executive-level staff.
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.